Biotech News

Gyre Therapeutics Reports Third Quarter 2026 and Year-to-Date Financial Results with Business Updates

Catalyst Biosciences (CBIO)Catalyst BiosciencesEarnings

Q3 2026 revenue of $32.9 million; GAAP basic EPS: $(0.04) Full year 2026 revenue guidance of $100.5 to $111.0 million affirmed SAN DIEGO, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Gyre Therapeutics, Inc. (Gyre, Gyre Therapeutics or the Company) (Nasdaq: GYRE), a U.S.

Related news

Catalyst Biosciences

Catalyst Biosciences was a biotechnology company focused on engineered proteins for hemostasis, complement, and related inflammatory biology before becoming a historical ticker. Its story was built around protein-engineering approaches to difficult disease pathways.

Recent company news

Stock data

Close
12.91 USD
Market cap
468.91M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States